Valsartan and Sacubitril

ApprovedSmall molecule

UUniversity Hospital Ostrava

Valsartan and Sacubitril is one of 26 small molecule programs targeting Heart Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart FailureApproved

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Valsartan and Sacubitril

UUniversity Hospital Ostrava

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Monoferric

PPharmacosmos A/S

Preclinical

5 4

Zemplar

Savaysa

Xifaxan

2 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Coumadin

AAbbott

Preclinical

1 9

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 10

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure1 trial

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Not yet recruiting·UUniversity Hospital Ostrava·Phase 4·NCT06035978·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Valsartan and Sacubitril. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Valsartan and Sacubitril compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Valsartan and Sacubitril. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Ostrava company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Hospital Ostrava

Valsartan and Sacubitril

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News